Literature DB >> 26820850

Correction: Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications.

Kavita Gandhi, Mahamadou A Thera, Drissa Coulibaly, Karim Traoré, Ando B Guindo, Amed Ouattara, Shannon Takala-Harrison, Andrea A Berry, Ogobara K Doumbo, Christopher V Plowe.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0101783.].

Entities:  

Year:  2016        PMID: 26820850      PMCID: PMC4731568          DOI: 10.1371/journal.pone.0148240

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Fig 5 is erroneously a duplicate of Fig 6. Please view the correct Fig 5 below. Additionally, the authors have provided revised captions for Fig 5 and Fig 6. Please view the corrected figure captions here.
Fig 5

Association between change in the predominant amino at a polymorphic site and the hazard of Plasmodium falciparum clinical disease.

The association between changes at polymorphic sites in Th2R and Th3R which occurred between consecutive clinical episodes and the hazard of clinical disease was calculated using a Cox proportional hazards model. To account for the possibility of treatment failure and to allow for time for allele-specific antibodies to the first of two paired consecutive infections to be present by the time of the second infection, time intervals two weeks or less between consecutive episodes were excluded from the analyses. No significant association between changes at polymorphic sites in Th2R and Th3R which occurred between a clinical episode and a consecutive asymptomatic infection and the hazard of clinical disease was found. Asterisks denote polymorphic amino acid positions that lacked power to detect a hazard ratio below 1.51.

Fig 6

Association between change in the predominant amino at a polymorphic site and the hazard of Plasmodium falciparum infection.

The association between changes at polymorphic sites in Th2R and Th3R which occurred between consecutive clinical episodes and the hazard of infection was calculated using a Cox proportional hazards model. To account for the possibility of treatment failure and to allow for time for allele-specific antibodies to the first of two paired consecutive infections to be present by the time of the second infection, time intervals two weeks or less between consecutive episodes were excluded from the analyses. No significant association between changes at polymorphic sites in Th2R and Th3R which occurred between consecutive clinical episodes and the hazard of infection was found. Asterisks denote polymorphic amino acid positions that lacked power to detect a hazard ratio below 1.51.

Association between change in the predominant amino at a polymorphic site and the hazard of Plasmodium falciparum clinical disease.

The association between changes at polymorphic sites in Th2R and Th3R which occurred between consecutive clinical episodes and the hazard of clinical disease was calculated using a Cox proportional hazards model. To account for the possibility of treatment failure and to allow for time for allele-specific antibodies to the first of two paired consecutive infections to be present by the time of the second infection, time intervals two weeks or less between consecutive episodes were excluded from the analyses. No significant association between changes at polymorphic sites in Th2R and Th3R which occurred between a clinical episode and a consecutive asymptomatic infection and the hazard of clinical disease was found. Asterisks denote polymorphic amino acid positions that lacked power to detect a hazard ratio below 1.51.

Association between change in the predominant amino at a polymorphic site and the hazard of Plasmodium falciparum infection.

The association between changes at polymorphic sites in Th2R and Th3R which occurred between consecutive clinical episodes and the hazard of infection was calculated using a Cox proportional hazards model. To account for the possibility of treatment failure and to allow for time for allele-specific antibodies to the first of two paired consecutive infections to be present by the time of the second infection, time intervals two weeks or less between consecutive episodes were excluded from the analyses. No significant association between changes at polymorphic sites in Th2R and Th3R which occurred between consecutive clinical episodes and the hazard of infection was found. Asterisks denote polymorphic amino acid positions that lacked power to detect a hazard ratio below 1.51.
  1 in total

1.  Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.

Authors:  Kavita Gandhi; Mahamadou A Thera; Drissa Coulibaly; Karim Traoré; Ando B Guindo; Amed Ouattara; Shannon Takala-Harrison; Andrea A Berry; Ogobara K Doumbo; Christopher V Plowe
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  1 in total
  2 in total

1.  Genetic Diversity, Repeat Motifs, and Natural Selection at the C-Terminal Knob-Associated Histidine Rich Protein (KAHRP) of Plasmodium falciparum Clinical Samples from Saudi Arabia.

Authors:  Saad M Bin Dajem; Md Atique Ahmed; Marie Fe F Bohol; Syeda Wasfeea Wazid; Mohammed I Shafeai; Fuad H Rudiny; Ali M Motaen; Kareem Morsy; Hani Alothaid; Ahmed A Al-Qahtani
Journal:  J Trop Med       Date:  2022-03-28

2.  Population genetic and biophysical evidences reveal that purifying selection shapes the genetic landscape of Plasmodium falciparum RH ligands in Chhattisgarh and West Bengal, India.

Authors:  Sharmistha Ghoshal; Pramita Chowdhury; Sanhita Ray; Mitashree Mitra; Sumana Datta Kanjilal; Srikanta Sen; Anjan Kr Dasgupta; Sanghamitra Sengupta
Journal:  Malar J       Date:  2020-10-14       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.